Recent CARM News
- Carmila : Lancement d’un programme de rachat d’actions pour 10 millions d’euros • Business Wire • 07/24/2024 05:56:00 PM
- Carmila: Launch of a Share Buyback Program for €10 Million • Business Wire • 07/24/2024 05:56:00 PM
- Carmila: 2024 Half-Year Financial Report Available • Business Wire • 07/24/2024 05:38:00 PM
- Carmila : Mise à disposition du rapport financier semestriel 2024 • Business Wire • 07/24/2024 05:38:00 PM
- Carmila : Résultats du premier semestre 2024 • Business Wire • 07/24/2024 03:49:00 PM
- Carmila: 2024 Half-Year Results • Business Wire • 07/24/2024 03:49:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/09/2024 11:30:18 AM
- Carmila: Resources Devoted to the Liquidity Contract as of 30 June 2024 • Business Wire • 07/05/2024 04:11:00 PM
- Carmila : Moyens portés au contrat de liquidité au 30 juin 2024 • Business Wire • 07/05/2024 04:11:00 PM
- Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L.233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des marchés financiers • Business Wire • 07/02/2024 03:45:00 PM
- Information Concerning the Total Number of Voting Rights and Share • Business Wire • 07/02/2024 03:45:00 PM
- Carmila : Finalisation de l’acquisition de Galimmo SCA • Business Wire • 07/01/2024 04:48:00 PM
- Carmila: Closing of the Acquisition of Galimmo SCA • Business Wire • 07/01/2024 04:48:00 PM
- Carisma Therapeutics Announces Changes to its Board of Directors • PR Newswire (US) • 07/01/2024 11:30:00 AM
- Carmila: Potential Stake Increase in Galimmo SCA to 99.9% • Business Wire • 07/01/2024 05:00:00 AM
- Carmila : Participation dans Galimmo SCA potentiellement portée à 99,9% • Business Wire • 07/01/2024 05:00:00 AM
- Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with Moderna • PR Newswire (US) • 06/27/2024 08:30:00 PM
- Carisma Therapeutics Granted FDA Fast Track Designation for CT-0525 for the Treatment of HER2-overexpressing Solid Tumors • PR Newswire (US) • 06/25/2024 11:30:00 AM
- Carisma Therapeutics to Participate in the Stifel 2024 Cell Therapy Forum • PR Newswire (US) • 06/25/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 11:06:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 08:32:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 08:30:21 PM
- Carisma Therapeutics Announces Adjournment of Annual Meeting of Stockholders • PR Newswire (US) • 06/13/2024 08:30:00 PM
- Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L.233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des marchés financiers • Business Wire • 06/05/2024 03:45:00 PM
- Information Concerning the Total Number of Voting Rights and Share • Business Wire • 06/05/2024 03:45:00 PM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM